Table 2.

Common treatment-related adverse events (≥20%) occurred in patients older than 50 years.

	All grades		Grade 3 or worse
Adverse events n(%)	Anlotinib (n=36)	Placebo (n=15)	Anlotinib (n=36)	Placebo (n=15)
All	36 (100.0)	13 (86.7)	20 (55.6)	8 (53.3)
Hypertension	21 (58.3)	5 (33.3)	5 (13.9)	2 (13.3)
Palmar-plantar erythrodysesthesia syndrome	20 (55.6)	3 (20.0)	6 (16.7)	0 (0.0)
Proteinuria	18 (50.0)	6 (40.0)	0 (0.0)	0 (0.0)
Hypertriglyceridemia	18 (50.0)	5 (33.3)	3 (8.3)	1 (6.7)
QT interval prolongation	14 (38.9)	2 (13.3)	0 (0.0)	0 (0.0)
Diarrhea	11 (30.6)	3 (20.0)	1 (2.8)	0 (0.0)
Fatigue	11 (30.6)	3 (20.0)	1 (2.8)	0 (0.0)
Hypercholesteremia	10 (27.8)	4 (26.7)	0 (0.0)	0 (0.0)
GGT elevation	10 (27.8)	2 (13.3)	1 (2.8)	0 (0.0)
Lipase elevation	9 (25.0)	4 (26.7)	4 (11.1)	3 (20.0)
Urine erythrocyte positive	9 (25.0)	3 (20.0)	0 (0.0)	0 (0.0)
ALT increase	9 (25.0)	2 (13.3)	0 (0.0)	0 (0.0)
LDL increase	9 (25.0)	1 (6.7)	0 (0.0)	0 (0.0)
Hoarseness	9 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)
AST increase	8 (22.2)	2 (13.3)	1 (2.8)	0 (0.0)
Amylase elevation	7 (19.4)	6 (40.0)	3 (8.3)	3 (20.0)
Conjugated bilirubin increase	7 (19.4)	2 (13.3)	1 (2.8)	0 (0.0)
Platelet count decrease	6 (16.7)	2 (13.3)	1 (2.8)	1 (6.7)
Pharyngalgia	6 (16.7)	1 (6.7)	2 (5.6)	1 (6.7)
Bilirubin increase	6 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)
LDH increase	6 (16.7)	0 (0.0)	1 (2.8)	0 (0.0)
Neutrophil count decrease	5 (13.9)	3 (20.0)	0 (0.0)	0 (0.0)
Anorexia	5 (13.9)	3 (20.0)	1 (2.8)	0 (0.0)